

**MINUTES OF TECHNICAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/25-05 (TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS FOR
DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 16th July 2025

Venue: BMSICL Conference Hall.

The **Technical Evaluation Committee Meeting** for **Tender No. BMSIC/DRUGS/25-05** was held on **16th July 2025** under the Chairmanship of Dr. Pramod Kumar Singh, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Shailesh Kumar, Special Secretary, Department of Health, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
5. Sh. Navneet Kumar, DGM (Drugs), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/25-05.
2. Tender floated date- 28/02/2025.
3. Last date of submission of online bids- 25/04/2025.

3. The Tender has been floated on e-proc2 Portal for 04 (Four) Drugs.

4. Total 14 (Fourteen) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S. N.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s Akums Drugs and Pharmaceuticals Limited	Ok	Received	Ok
2	M/s Alkem Laboratories Ltd.	Ok	Received	Ok
3	M/s Bajaj Healthcare Limited	Ok	Received	Ok
4	M/s Bharat Serums and Vaccines Limited	Ok	Received	Ok
5	M/s Biosynergy Lifecare Private Limited	Ok	Received	Ok
6	M/s East African (India) Overseas	Ok	Received	Ok
7	M/s Emcure Pharmaceuticals Limited	Ok	Received	Ok
8	M/s Eskag Pharma Private Limited	Ok	Received	Ok
9	M/s Hindustan Polyfab	Ok	Received	Ok
10	M/s Morepen Laboratories Limited	Ok	Received	Ok
11	M/s Nixi Laboratories Private Limited	Ok	Received	Ok
12	M/s Precise Biopharma Pvt. Ltd.	Ok	Received	Ok
13	M/s Swiss Parenterals Limited	Ok	Received	Ok
14	M/s Unicare India Limited	Ok	Received	Ok

5. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Apixaban 5 mg Tablet	M/s Alkem Laboratories Ltd.	1
2	Ferric Carboxymaltose 50 mg/ml Injection 10 ml Vial	M/s Akums Drugs and Pharmaceuticals Limited	9
		M/s Bajaj Healthcare Limited	
		M/s Bharat Serums and Vaccines Limited	

		M/s East African (India) Overseas	
		M/s Emcure Pharmaceuticals Limited	
		M/s Eskag Pharma Private Limited	
		M/s Nixi Laboratories Private Limited	
		M/s Precise Biopharma Pvt. Ltd.	
		M/s Swiss Parenterals Limited	
3	Gabapentin 100 mg Tablet	M/s East African (India) Overseas	3
		M/s Morepen Laboratories Limited	
		M/s Unicure India Limited	
4	Ofloxacin 200 mg/100 ml Infusion	M/s Alkem Laboratories Ltd.	3
		M/s Biosynergy Lifecare Private Limited	
		M/s Hindustan Polyfab	

6. The summary of Bid received status was as follows:

1. Single Bid received for **01 Drug**.
2. Multiple Bids received for **03 Drugs**.

7. It was therefore unanimously decided by TEC in its meeting dated 28.04.2025 to recommend for Re-tender of Drugs at NIT S.N.- 1 (**01 Drug**) due to single bid condition and to evaluate the bids for Drugs at NIT S.N.- 2, 3 & 4 (**03 Drugs**) for which multiple bids have been received

8. The Preliminary Evaluation of technical bids from the aforementioned bidding firms was conducted by the assigned team, including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the BMSICL website, and claims/objections were invited online vide notice no. 2480 dated 06/06/2025 on e-proc2.

9. After evaluating the clarifications received from the bidders in response to the notice and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings for each firm were recorded in today's meeting with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	NIT S.N.	Name of the Drug	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	2	Ferric Carboxymaltose 50 mg/ml Injection 10 ml Vial	M/s Akums Drugs and Pharmaceuticals Limited	Qualified	Ok
			M/s Bajaj Healthcare Limited	Qualified	Ok
			M/s Bharat Serums and Vaccines Limited	Qualified	Ok
			M/s East African (India) Overseas	Qualified	Ok
			M/s Emcure Pharmaceuticals Limited	Qualified	Ok
			M/s Eskag Pharma Private Limited	Qualified	Ok
			M/s Nixi Laboratories Private Limited	Qualified	Ok
			M/s Precise Biopharma Pvt. Ltd.	Qualified	Ok
			M/s Swiss Parenterals Limited	Qualified	Ok

2	3	Gabapentin 100 mg Tablet	M/s East African (India) Overseas	Qualified	Ok
			M/s Morepen Laboratories Limited	Qualified	Ok
			M/s Unicare India Limited	Disqualified	UDIN generated for FY 2021-22 is not within the stipulated period and Turnover Amount is also not mention at UDIN Document Details. Thus, the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years as per clause 3(l) not submitted
3	4	Ofloxacin 200 mg/100 ml Infusion	M/s Alkem Laboratories Ltd.	Disqualified	Product approval. MSC & Valid Pollution Control Certificate as per Clause 3(f), WHO-GMP/GMP as per Clause 3(j), MPCC as per Clause 3(k)& Annexure VI as per Clause 5(l) not submitted
			M/s Biosynergy Lifecare Private Limited	Disqualified	UDIN Number not mentioned for F.Y 2021-22, F.Y 2022-23, F.Y 2023-24, hence amount cannot be verified. Thus, the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years as per clause 3(l) not submitted

			M/s Hindustan Polyfab	Disqualified	UDIN given by the firm for FY 2022-23 consists of 17 digits only, hence amount cannot be verified. Thus, the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years as per clause 3(l) not submitted
--	--	--	-----------------------	---------------------	--

10. According to the comparative chart above, a total of ten (10) bidders namely, M/s Akums Drugs and Pharmaceuticals Limited, M/s Bajaj Healthcare Limited, M/s Bharat Serums and Vaccines Limited, M/s East African (India) Overseas, M/s Emcure Pharmaceuticals Limited, M/s Eskag Pharma Private Limited, M/s Morepen Laboratories Limited, M/s Nixi Laboratories Private Limited, M/s Precise Biopharma Pvt. Ltd. & M/s Swiss Parenterals Limited were found technically qualified notwithstanding their product wise qualification status as mentioned above.

11. A total of four (04) firms namely, M/s Alkem Laboratories Ltd., M/s Biosynergy Lifecare Private Limited, M/s Hindustan Polyfab & M/s Unicare India Limited were found technically disqualified.

12. The manufacturing unit of the eight (08) technically qualified firms namely, M/s Akums Drugs and Pharmaceuticals Limited, M/s Bajaj Healthcare Limited, M/s Bharat Serums and Vaccines Limited, M/s East African (India) Overseas, M/s Morepen Laboratories Limited, M/s Nixi Laboratories Private Limited, M/s Precise Biopharma Pvt. Ltd. & M/s Swiss Parenterals Limited were inspected during last three years and/or having valid rate contract with BMSICL.

13. It was therefore unanimously decided to recommend for factory inspection of remaining two (02) technically qualified firms i.e., M/s Emcure Pharmaceuticals Limited & M/s Eskag Pharma Private Limited.

14. The meeting thus concluded with a vote of thanks.

Sd/-
(Navneet Kumar)
DGM (Drugs), BMSICL, Patna.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C Procurement,
SHSB.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Shailesh Kumar)
Special Secretary, Department of Health, GoB.

Sd/-
(Dr. Pramod Kumar Singh)
Director in Chief, Health Dept., Govt. of Bihar.